罗拉吡坦(rolapitant)是由TESARO公司开发的选择性、竞争性人类P物质/神经激肽-1(NK1)受体拮抗剂,商品名为Varubi。2015年9月1日,罗拉吡坦由美国FDA批准上市,用于治疗延长期化疗导致的恶心呕吐,也可与其他呕吐药合用,用于防治肿瘤化疗导致的恶心呕吐的发作。罗拉吡坦的中文化学名称:(5S,8S)-8-[{1(R)-(3, Rolapitant is a selective and competitive human substance P / neurokinin-1 (NK1) receptor antagonist developed by TESARO Company under the tradename Varubi. On September 1, 2015, Ropylatine was approved by the US FDA for its use in the treatment of prolonged chemotherapy-induced nausea and vomiting. It may also be used in combination with other vomiting agents to prevent and treat the onset of nausea and vomiting induced by chemotherapy. Ropitron’s Chinese chemical name: (5S, 8S) -8 - [{1 (R) - (3,